Moderators:

• Katherine Moxley, MD, Stephenson Cancer Center, Oklahoma City, OK

Speakers:

• Debra Richardson, MD, University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK
• David O’Malley, MD, The Ohio State University, Columbus, OH
• Katherine Moxley, MD, Stephenson Cancer Center, Oklahoma City, OK

Description: With the recent FDA-approvals of poly (ADP ribose) polymerase (PARP) inhibitors in subsets of high grade serous ovarian and PD-1 inhibitors in specific subsets of endometrial and cervical cancer, targeted therapy has become a reality that has rapidly been incorporated into clinical practice. Despite approvals by disease site, the ability to translate molecular alterations specific to an individual patient’s tumor remains challenging. National, collaborative, interdisciplinary trials such as the NCI Molecular Analysis for Therapy Choice (MATCH), SWOG Dual Anti–CTLA-4 and Anti­–PD-1 Blockade in Rare Tumors (DART) and ASCO Targeted Agent and Profiling Utilization Registry (TAPUR) studies have been undertaken to enhance scientific knowledge of targeted therapy as it applies to patient-specific response. This session will review the current state of the scientific rationale behind targeted therapy, ongoing trial initiatives and future directions for improving “precision medicine” in the clinical setting.

Location: Kalakaua A